CoChat

Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study

The DOI matches its Crossref record; 22 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND Glucokinase acts as a glucose sensor in the pancreas and a glucose processor in the liver, and has a central role in glucose homoeostasis. Dorzagliatin is a new, dual-acting, allosteric glucokinase activator that targets both pancreatic and hepatic glucokinases. Dorzagliatin has good pharmacokinetic and pharmacodynamic properties in humans, and provides effective 24-h glycaemic control and improves glucose sensitivity in patients with type 2 diabetes. We aimed to assess the efficacy and safety of dorzagliatin monotherapy at different doses in Chinese patients with type 2 diabetes. METHODS In this multicentre, randomised, double-blind, placebo-controlled, phase 2 study, we randomly assigned (1:1:1:1:1) patients to receive oral placebo or one of four doses of oral dorzagliatin (75 mg once a day, 100 mg once a day, 50 mg twice a day, or 75 mg twice a day) using permuted-block randomisation, with a block size of ten and without stratification. Eligible patients were men or non-fertile women (aged 40-75 years) with type 2 diabetes who had a BMI of 19·0-30·0 kg/m2, were on a diet and exercise regimen, and were previously untreated or treated with metformin or α-glucosidase inhibitor monotherapy. The study started with a 4-week placebo run-in period followed by a 12-week treatment period. The primary endpoint was the change in HbA1c from baseline to week 12, which was assessed in all patients who received at least one dose of study drug and had both baseline and at least…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(18)30105-0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Research works printed but not linked: 3

  1. Li, 2016, R&D strategies for type 2 diabetes: elucidate the underlying pathology and improve the impaired organ functions, Prog Pharm Sci, 40, 161
  2. Yu, 2016, Research progress in glucokinase activators, Prog Pharm Sci, 40, 168
  3. Zhu X-X, Zhu D-L, Li X-Y, et al. Dorzagliatin (HMS5552), a novel dual acting glucokinase activator, improves glycemic control and pancreatic β-cell function in patients with type 2 diabetes: a 28-day treatment study using biomarker-guided patient selection. Diabetes Obes Metab (in press).

Cited by

See all 96

Metadata

Authors
Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., Zeng, J., Wang, G., Zhao, W., Zhang, Q., Li, Y., Fang, H., Lv, X., Shi, Y., Tian, H., Ji, L., Gao, X., Zhang, L., Bao, Y., Lei, M., Li, L., Zeng, L., Li, X., Hou, X., Zhao, Y., Hu, T., Ge, X., Zhao, G., Li, Y., Zhang, Y., & Chen, L.
Affiliations
  • Nanjing Drum Tower Hospital (CN)
  • The First People's Hospital of Changde (CN)
  • Jilin University (CN)
  • Nanjing First Hospital (CN)
  • Jinan Central Hospital (CN)
  • Chenzhou First People's Hospital (CN)
  • Sun Yat-sen University (CN)
  • First Hospital of Jilin University (CN)
  • Affiliated Hospital of Qingdao University (CN)
  • First Affiliated Hospital of Anhui Medical University (CN)
  • Third Hospital of Hebei Medical University (CN)
  • Tangshan Gongren Hospital (CN)
  • Shanghai Changzheng Hospital (CN)
  • Sichuan University (CN)
  • Peking University People's Hospital (CN)
  • Fudan University (CN)
  • Second Hospital of Hebei Medical University (CN)
  • Shanghai Jiao Tong University (CN)
  • Xiangya Hospital Central South University (CN)
  • China Medical University (CN)
  • Hua Medicine (China) (CN)
Corresponding author
Chen, Li
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2018-08
Volume
6
Issue
8
Pages
627-636
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2801191096
Cited by
96
References
24
Citations by year
2026: 5 · 2025: 9 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 11 · 2020: 8 · 2019: 4 · 2018: 4
FWCI
5.41
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Major Scientific and Technological Special Project for Significant New Drugs Development (2014ZX09101002004)
  • Shanghai Science and Technology Innovation Action Project (14431908300, 15XD1520500)
  • Shanghai Pudong District Science and Technology Innovation Action Project (PKJ2014-S06)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
dorzagliatin, type 2 diabetes, glucokinase activators, monotherapy, dose-ranging, HbA1c, glycemic control, Chinese patients, drug safety, adverse events, hypoglycemia, drug-drug interactions, pharmacokinetics, pharmacodynamics, hepatic glucokinase, antidiabetic drugs, metformin
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Middle Aged, Prognosis, Pyrazoles, Biomarkers, Enzyme Activators, Asian People

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. https://app.cochat.ai/papers/10.1016/s2213-8587(18)30105-0
The paper
Zhu, D., Gan, S., Liu, Y., Ma, J., Dong, X., Song, W., Zeng, J., Wang, G., Zhao, W., Zhang, Q., Li, Y., Fang, H., Lv, X., Shi, Y., Tian, H., Ji, L., Gao, X., Zhang, L., Bao, Y., . . . Chen, L. (2018). Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(18)30105-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.